GleamWall
中文EN

PRQR ProQR Therapeutics N.V. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1612940 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-15.9%
TTM net income YoY-51.9%
TTM EPS YoY-25.0%
Revenue 3-yr CAGR64.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-273.1%
Net margin-265.2%
FCF margin-338.3%
EBITDA margin—

Returns

ROE-61.2%
ROA-30.1%
ROIC (approx.)—
Asset turnover0.11x

Leverage & solvency

Liabilities / assets56.2%
Debt / equity0.00x
Current ratio3.09x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.25x
Accruals ratio7.6%
Payout ratio—
Capex / revenue6.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR 2025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-302024Q22024-06-302024Q12024-03-31
Income statement
Revenue4.69M2.88M3.82M4.52M4.31M3.84M6.30M4.45M
R&D expense9.92M11.08M11.41M12.32M10.61M9.41M7.05M9.28M
SG&A expense3.89M3.12M4.82M3.23M3.91M3.28M3.01M3.45M
Operating income-9.10M-11.28M-12.25M-10.82M-10.08M-8.72M-3.60M-8.07M
Pretax income-8.92M-11.01M-12.16M-10.08M-9.30M-8.11M-2.89M-7.66M
Income tax1,000018,000—00-200,0003,000
Net income-8.92M-11.01M-12.18M-10.08M-9.30M-8.11M-2.69M-7.66M
EPS (basic)—-0.10-0.12-0.10—-0.10-0.03-0.09
EPS (diluted)—-0.10-0.12-0.10—-0.10-0.03-0.09
Weighted avg. shares (diluted)—105.34M105.34M105.30M—81.68M81.67M81.57M
Balance sheet
Cash & equivalents92.41M106.88M119.77M132.41M149.41M89.40M78.97M85.71M
Short-term investments——————17.18M17.00M
Receivables6.80M———3.75M———
Current assets100.13M111.33M124.28M138.08M153.84M92.41M101.77M107.16M
PP&E, netmay include right-of-use assets (IFRS)12.63M13.02M13.26M13.61M14.11M14.44M16.29M16.72M
Total assets112.76M124.35M137.54M151.69M167.96M106.85M118.05M123.88M
Current liabilities32.44M33.14M33.09M33.72M38.90M39.64M37.28M34.42M
Short-term debt4.87M4.80M4.73M4.66M4.58M4.51M4.44M4.37M
Total liabilities63.38M67.28M70.55M72.75M79.40M81.87M85.20M89.06M
Shareholders' equity49.37M57.07M66.98M78.94M88.56M24.98M32.85M34.82M
Cash flow statement
Operating cash flow-13.36M-12.23M-11.40M-15.80M-9.35M-5.66M-6.26M-15.13M
Capital expenditure526,000169,000101,000224,000133,000286,000267,000732,000
Free cash flow-13.88M-12.40M-11.50M-16.02M-9.48M-5.94M-6.52M-15.86M
Investing cash flow-526,000-169,000-101,000-224,000-2.79M16.71M-267,000-17.73M
Financing cash flow-599,000-444,000-293,000-500,00071.43M-453,000-282,000-419,000
Stock-based compensation1.23M1.12M909,000758,000568,000612,000628,000736,000

Free plan shows the latest 8 periods; Pro shows all 32 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.